Search results Search for: Search Refine your results by duration: Any Under 5 mins Under 20 mins Over 20 mins Sort by: Relevance Views Date Novel In Vitro and In Vivo Drug Screening Platform for ALL Bandana Ajay Vishwakarma, PhD Join us for our ASH 2021 poster walkthrough webinar 5 months ago | 7 mins Evaluation of Acute Myeloid Leukemia by high parameter flow cytometry Greg Bannish, PhD, Flow Cytometry Subject Matter Expert, Champions Oncology Acute Myeloid leukemia (AML) is a specific type of cancer in which the bone marrow makes abnormal myeloblasts, red blood cells and platelets. AML is ... 2 years ago | 28 mins 2D Ex Vivo Patient-derived AML Platform for testing Molecular-Targeted Therapies Bandana Vishwakarma, PhD, Scientist in Hematology Oncology at Champions Oncology Champions Oncology was excited to participate in the American Association of Cancer Research’s (AACR) Virtual Meeting in June. Due the limited availab... 2 years ago | 22 mins Principles Of CAR T-Cell Therapy And The Pathway To Regulatory Approval Brian Marks and Ashley Jones For many years, the primary forms of cancer treatment have been chemotherapy, radiation and surgery, but the toughest forms of cancer demand breakthro... 1 year ago | 36 mins Lymphomas and Leukemias Jeff Gordon Leukemia and lymphoma are hematologic neoplasms that affect members of all age groups. Each year, over 140,000 people in the US are diagnosed with a h... 4 years ago | 63 mins Establishment of a Patient-derived B-ALL Ex Vivo Platform Bandana Vishwakarma, PhD, Scientist in Hematology Oncology at Champions Oncology Champions Oncology was excited to participate in the American Association of Cancer Research’s (AACR) Virtual Meeting in June. Due the limited availab... 2 years ago | 23 mins It’s in the blood: Patient-derived hematologic malignancy models in research Amy Wesa, PhD, Director of Immuno-Oncology Research, Champions Oncology Hematological malignancies are cancers that begin in the cells of blood-forming tissue or in the cells of the immune system. These types of cancer, s... 2 years ago | 35 mins Targeting IDH mutations in Cancer Brandon Nicolay, PhD, Associate Director, Pharmacology, Agios Pharmaceuticals Somatic mutations in the enzyme isocitrate dehydrogenase 1 (IDH1) arise in roughly 6–10% of patients with acute myeloid leukemia (AML). These mutation... 2 years ago | 34 mins Next Generation Humanized Mice for AML and NK Cell Therapy Testing Amy Wesa, PhD, Director of Immuno-Oncology Research at Champions Oncology To develop the most successful novel agents for cancer, researchers require preclinical models that fundamentally epitomize patient populations to ena... 2 years ago | 55 mins Next Generation Humanized Mice for AML and NK Cell Therapy Testing Amy Wesa, PhD, Director of Immuno-Oncology Research at Champions Oncology To develop the most successful novel agents for cancer, researchers require preclinical models that fundamentally epitomize patient populations to ena... 2 years ago | 56 mins
